Get an early diagnosis for viral hepatitis with Echosens Fibrometer Virus test
Advances in management of hepatitis has been an ongoing process. However coming up with a non-invasive technology for early screening and diagnosis of fibrosis and cirrhosis has been one of the lastest of SRL Diagnostics. One can now get an early diagnosis of viral hepatitis with SRL Diagnostics‘ Echosens Fibrometer Virus test.
Viral Hepatitis is a silent killer as it rarely presents symptoms until very late. It is estimated that about 20 million Indians are Hepatitis B carriers and about 8 to 10 million have Hepatitis C Virus (HCV) infection. According to a study conducted by SRL Diagnostics 4% Indians are carrier of Hepatitis B Virus (HBV) & 1.9% Indians are infected with HCV. HCV is known to cause chronic liver diseases (CLD) in 50% of cases whereas HBV causes CLD in 20% of cases. Management of chronic viral hepatitis is challenging since progression of disease varies significantly from patient to patient. Available tools (i.e. liver enzymes, viral load or genotyping) sufficiently aid in monitoring of viral infection, however these tools do not provide accurate estimate of the rate of progression of liver damage. Liver biopsy remains the gold standard for assessing liver damage and presently it is done only in non-responding patientswith advanced stage of infection.
The new Echosens Fibrometer Virus test providing accurate and non-invasive tool for assessing liver damage, has been launched by SRL Diagnostics Limited (SRL) in collaboration with Echosens France about a year ago. The Echosens Fibrometer Virus test is available across SRL Diagnostics Labs in India at a minimal cost of Rs. 3, 450. Chronic Viral Hepatitis patients with or without HIV co-infection are ideal candidates for this test and can consider it after appropriate consultation with treating clinician.
Echosens Fibrometer Virus test has been extensively evaluated through robust clinical studies and has demonstrated highest possible accuracy in assessing liver damage i.e. fibrosis or cirrhosis. This test provides a safe and convenient means for two clinically relevant end points: detection of significant fibrosis (indication for antiviral treatment) and detection of cirrhosis (screening for eosphageal varices and hepatocellular carcinoma).